Graft Versus Host Disease (GVHD) Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1067442
  • December 2021
  • Pharmaceuticals
  • 125 Pages
Report Description

This report is a comprehensive study that examines the Graft Versus Host Disease (GVHD) industry in depth. With reference to key regions and major nations, the study specifies the product type of Graft Versus Host Disease (GVHD) as well as its use in various industrial verticals. Furthermore, the report identified and analysed all of the top companies functioning in the global Graft Versus Host Disease (GVHD) market arena, comparing and contrasting them based on market revenue, yearly sales volume, historical growth rate, and company strategies. The worldwide Graft Versus Host Disease (GVHD) market research offers a business strategy for current market participants to strengthen their market positions based on all of these findings. Furthermore, the paper recommends a market entry strategy for newcomers to the sector.

The top vendors and distributors operating in all of the major regions have also been highlighted in the Graft Versus Host Disease (GVHD) market report. This data and research should aid market players in strengthening their market distribution networks and expanding their geographic reach.
 
Graft Versus Host Disease (GVHD) Market Strategic Analysis 

The market was studied using several marketing methodologies such as Porter's Five Forces Analysis, player positioning analysis, SWOT analysis, market share analysis, and value chain analysis in the Graft Versus Host Disease (GVHD) market study. The market dynamics and factors such as the threat of a Graft Versus Host Disease (GVHD) substitute, the threat of new entrants into the Graft Versus Host Disease (GVHD) market, buyer bargaining power, supplier bargaining power to Graft Versus Host Disease (GVHD) providing companies, and internal rivalry among Graft Versus Host Disease (GVHD) providers are analysed in Porter's Five Forces analysis to provide the report's readers with a detailed view of the current market dynamics.

This analysis assists report users in evaluating the Graft Versus Host Disease (GVHD) market based on various parameters such as economies of scale, switching costs, brand loyalty, existing distribution channels, capital investments, manufacturing rights & patents, government regulations, advertising impact, and consumer preference impact. This simplified data is expected to aid the industry's key decision-makers in their decision-making process. Furthermore, this study answers the crucial question of whether or not new entrants should enter the Graft Versus Host Disease (GVHD) industry.
 
Graft Versus Host Disease (GVHD) Market Key Trends Analysis

The important factors influencing the growth of the Graft Versus Host Disease (GVHD) market have been examined in this report. The driving factors that are boosting demand for Graft Versus Host Disease (GVHD)s and the restraining factors that are slowing growth of the Graft Versus Host Disease (GVHD) industry are addressed in depth, as well as their implications for the worldwide Graft Versus Host Disease (GVHD) market. In addition, the published analysis identifies and discusses in detail the trends that are driving the market and impacting its growth. In addition, other qualitative variables such as risks connected with operations and key problems faced by market players are covered in the report.

Graft Versus Host Disease (GVHD) Market Key Segment Analysis

By segmenting the market by product type, application, and geography, the study provides a clear picture of the Graft Versus Host Disease (GVHD) industry. On the basis of current and future trends, all segments of the Graft Versus Host Disease (GVHD) industry have been examined. The market and its divisions are forecasted for the years 2021 through 2028. The study identifies the categories that are contributing the most to total market revenue growth, as well as the factors that are supporting their growth.

The research will provide a detailed qualitative and quantitative product type segment analysis for the years 2021 to 2028.

The report study analyses and includes a variety of prospective prospects and aspects affecting various applications.
 
Graft Versus Host Disease (GVHD) Market Regional Trends and Market Player’s Analysis

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the regions in which the market is divided. In 2020, the worldwide Graft Versus Host Disease (GVHD) market was dominated by North America. The Asia Pacific region is expected to have the highest CAGR for the Graft Versus Host Disease (GVHD) market throughout the projected period.


 
The market revenue, market shares, business strategies, recent developments, and growth rates of major players with substantial market shares in the global Graft Versus Host Disease (GVHD) market are all examined. These firms' recent developments, such as new solution/product launches, research projects, acquisitions, geographic expansions, and technological advancements, are taken into account when determining their position in the Graft Versus Host Disease (GVHD) market. All important stakeholders in the Graft Versus Host Disease (GVHD) value chain and technological ecosystem are expected to benefit from the insights offered in the Graft Versus Host Disease (GVHD) market research study.

In order to provide a broader understanding of the top competitors in the Graft Versus Host Disease (GVHD) market, the research includes a company market share analysis. AltruBio, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, CSL Behring, CTI BioPharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Equillium/Biocon, GlaxoSmithKline, Incyte Corporation, Jazz Pharmaceuticals, Kadmon Corporation, MaaT Pharma, Medac, Millennium Pharmaceuticals/Takeda Oncology, Novartis, OncoImmune/Merck (MSD), Pfizer, Regimmune Corporation, Roche-Genentech, Syndax Pharmaceutical, Synthetic Biologics, Takeda, Xenikos are among the major participants in the global Graft Versus Host Disease (GVHD) industry.
 
Scope of the report
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2021
Forecast Period Covered 2021-2028
Units for value Revenue in USD million and CAGR from 2021 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered AltruBio, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, CSL Behring, CTI BioPharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Equillium/Biocon, GlaxoSmithKline, Incyte Corporation, Jazz Pharmaceuticals, Kadmon Corporation, MaaT Pharma, Medac, Millennium Pharmaceuticals/Takeda Oncology, Novartis, OncoImmune/Merck (MSD), Pfizer, Regimmune Corporation, Roche-Genentech, Syndax Pharmaceutical, Synthetic Biologics, Takeda, Xenikos
 
Major Highlights of the Graft Versus Host Disease (GVHD) Market report study:
  • An in-depth examination of the global Graft Versus Host Disease (GVHD) industry will be published soon.
  • The study examines the global Graft Versus Host Disease (GVHD) market and offers major actionable information to its players.
  • The research has taken into account all key events in the recent past, providing users with up-to-date industry information.
  • The report study is expected to aid the industry's key decision-makers in their decision-making process.
  • Data on market intelligence, changing market dynamics, existing and predicted market trends, and so on are included in the report.
  • The research includes a detailed examination of the macroeconomic and microeconomic aspects that influence the global Graft Versus Host Disease (GVHD) industry.
  • The Market Ecosystem and Adoption in Different Markets
  • The global Graft Versus Host Disease (GVHD) market is being shaped by several major trends.
  • The size of the Graft Versus Host Disease (GVHD) market in terms of revenue has been measured in the past and will be measured in the future in USD million.
  • Consumer preference patterns and recent industrial developments
  • The worldwide Graft Versus Host Disease (GVHD) market's competitive landscape and player positioning analysis
  • Major players' key goods and solutions, as well as their business strategies
  • Recommendations for new market entrants as well as existing market participants.
  • The study of niche and potential segments (product type, application, and regions/countries) predicts that promising growth will be noticed.
  • Operating players in the market encounter a number of significant hurdles.
  • An examination of the major risks involved in market operations
 
The report segment of the global Graft Versus Host Disease (GVHD) market as follows:
Global Graft Versus Host Disease (GVHD) Market: By Product Type

  • Type I
  • Type II
  • Type III

Global Graft Versus Host Disease (GVHD) Market: By Application
  • Application I
  • Application II
  • Application III

Global Graft Versus Host Disease (GVHD) Market: By Region
  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China 
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

The report study is drafted to provide actionable insights to the following mentioned audience:
  • Institutes of research and consulting firms
  • Companies are attempting to get into the Graft Versus Host Disease (GVHD) market.
  • Universities and students
  • Other companies in the Graft Versus Host Disease (GVHD) market include solution providers, product producers, service providers, and others.
  • Private companies and government agencies that are linked
  • Individuals interested in learning more about the Graft Versus Host Disease (GVHD) market

Manufacturers and Segments

  • AltruBio
  • Amgen
  • AstraZeneca
  • Biogen
  • Bristol-Myers Squibb
  • CSL Behring
  • CTI BioPharma
  • ElsaLys Biotech (Mediolanum Farmaceutici Spa)
  • Equillium/Biocon
  • GlaxoSmithKline
  • Incyte Corporation
  • Jazz Pharmaceuticals
  • Kadmon Corporation
  • MaaT Pharma
  • Medac
  • Millennium Pharmaceuticals/Takeda Oncology
  • Novartis
  • OncoImmune/Merck (MSD)
  • Pfizer
  • Regimmune Corporation
  • Roche-Genentech
  • Syndax Pharmaceutical
  • Synthetic Biologics
  • Takeda
  • Xenikos
  • Type I
  • Type II
  • Type III
  • Application I
  • Application II
  • Application III

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Graft Versus Host Disease (GVHD) Market Snapshot
          2.1.1. Global Graft Versus Host Disease (GVHD) Market By Type I,2019
               2.1.1.1.
               2.1.1.2.Type I I
               2.1.1.3.Type I II
          2.1.2. Global Graft Versus Host Disease (GVHD) Market By Application I,2019
               2.1.2.1.
               2.1.2.2.Application I I
               2.1.2.3.Application I II
          2.1.3. Global Graft Versus Host Disease (GVHD) Market By End-use,2019
          2.1.4. Global Graft Versus Host Disease (GVHD) Market By Geography,2019

3. Global Graft Versus Host Disease (GVHD) Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Graft Versus Host Disease (GVHD) Market Size (US$), By Type I, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type I, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type I, 2020
     4.2. Global Graft Versus Host Disease (GVHD) Market Size (US$), By Type I, 2018 – 2028

5. Global Graft Versus Host Disease (GVHD) Market Size (US$), By Application I, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application I, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application I, 2020
     5.2. Global Graft Versus Host Disease (GVHD) Market Size (US$), By Application I, 2018 – 2028

6. Global Graft Versus Host Disease (GVHD) Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Graft Versus Host Disease (GVHD) Market Size (US$), By End-use, 2018 – 2028

7. Global Graft Versus Host Disease (GVHD) Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Graft Versus Host Disease (GVHD) Market Analysis, 2018 – 2028 
          7.2.1. North America Graft Versus Host Disease (GVHD) Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Graft Versus Host Disease (GVHD) Market Size (US$), By Type I, 2018 – 2028
          7.2.3. North America Graft Versus Host Disease (GVHD) Market Size (US$), By Application I, 2018 – 2028
          7.2.4. North America Graft Versus Host Disease (GVHD) Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Graft Versus Host Disease (GVHD) Market Analysis, 2018 – 2028 
          7.3.1.  Europe Graft Versus Host Disease (GVHD) Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Graft Versus Host Disease (GVHD) Market Size (US$), By Type I, 2018 – 2028
          7.3.3. Europe Graft Versus Host Disease (GVHD) Market Size (US$), By Application I, 2018 – 2028
          7.3.4. Europe Graft Versus Host Disease (GVHD) Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Graft Versus Host Disease (GVHD) Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Graft Versus Host Disease (GVHD) Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Graft Versus Host Disease (GVHD) Market Size (US$), By Type I, 2018 – 2028
          7.4.3. Asia Pacific Graft Versus Host Disease (GVHD) Market Size (US$), By Application I, 2018 – 2028
          7.4.4. Asia Pacific Graft Versus Host Disease (GVHD) Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Graft Versus Host Disease (GVHD) Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Graft Versus Host Disease (GVHD) Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Graft Versus Host Disease (GVHD) Market Size (US$), By Type I, 2018 – 2028
          7.5.3. Latin America Graft Versus Host Disease (GVHD) Market Size (US$), By Application I, 2018 – 2028
          7.5.4. Latin America Graft Versus Host Disease (GVHD) Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Graft Versus Host Disease (GVHD) Market Analysis, 2018 – 2028 
          7.6.1.  MEA Graft Versus Host Disease (GVHD) Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Graft Versus Host Disease (GVHD) Market Size (US$), By Type I, 2018 – 2028
          7.6.3. MEA Graft Versus Host Disease (GVHD) Market Size (US$), By Application I, 2018 – 2028
          7.6.4. MEA Graft Versus Host Disease (GVHD) Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Graft Versus Host Disease (GVHD) Providers
        8.4.1 AltruBio
                8.4.1.1 Business Description
                8.4.1.2 AltruBio Geographic Operations
                8.4.1.3 AltruBio Financial Information
                8.4.1.4 AltruBio Product Positions/Portfolio
                8.4.1.5 AltruBio Key Developments
        8.4.2 Amgen
                8.4.2.1 Business Description
                8.4.2.2 Amgen Geographic Operations
                8.4.2.3 Amgen Financial Information
                8.4.2.4 Amgen Product Positions/Portfolio
                8.4.2.5 Amgen Key Developments
        8.4.3 AstraZeneca
                8.4.3.1 Business Description
                8.4.3.2 AstraZeneca Geographic Operations
                8.4.3.3 AstraZeneca Financial Information
                8.4.3.4 AstraZeneca Product Positions/Portfolio
                8.4.3.5 AstraZeneca Key Developments
        8.4.4 Biogen
                8.4.4.1 Business Description
                8.4.4.2 Biogen Geographic Operations
                8.4.4.3 Biogen Financial Information
                8.4.4.4 Biogen Product Positions/Portfolio
                8.4.4.5 Biogen Key Developments
        8.4.5 Bristol-Myers Squibb
                8.4.5.1 Business Description
                8.4.5.2 Bristol-Myers Squibb Geographic Operations
                8.4.5.3 Bristol-Myers Squibb Financial Information
                8.4.5.4 Bristol-Myers Squibb Product Positions/Portfolio
                8.4.5.5 Bristol-Myers Squibb Key Developments
        8.4.6 CSL Behring
                8.4.6.1 Business Description
                8.4.6.2 CSL Behring Geographic Operations
                8.4.6.3 CSL Behring Financial Information
                8.4.6.4 CSL Behring Product Positions/Portfolio
                8.4.6.5 CSL Behring Key Developments
        8.4.7 CTI BioPharma
                8.4.7.1 Business Description
                8.4.7.2 CTI BioPharma Geographic Operations
                8.4.7.3 CTI BioPharma Financial Information
                8.4.7.4 CTI BioPharma Product Positions/Portfolio
                8.4.7.5 CTI BioPharma Key Developments
        8.4.8 ElsaLys Biotech (Mediolanum Farmaceutici Spa)
                8.4.8.1 Business Description
                8.4.8.2 ElsaLys Biotech (Mediolanum Farmaceutici Spa) Geographic Operations
                8.4.8.3 ElsaLys Biotech (Mediolanum Farmaceutici Spa) Financial Information
                8.4.8.4 ElsaLys Biotech (Mediolanum Farmaceutici Spa) Product Positions/Portfolio
                8.4.8.5 ElsaLys Biotech (Mediolanum Farmaceutici Spa) Key Developments
        8.4.9 Equillium/Biocon
                8.4.9.1 Business Description
                8.4.9.2 Equillium/Biocon Geographic Operations
                8.4.9.3 Equillium/Biocon Financial Information
                8.4.9.4 Equillium/Biocon Product Positions/Portfolio
                8.4.9.5 Equillium/Biocon Key Developments
        8.4.10 GlaxoSmithKline
                8.4.10.1 Business Description
                8.4.10.2 GlaxoSmithKline Geographic Operations
                8.4.10.3 GlaxoSmithKline Financial Information
                8.4.10.4 GlaxoSmithKline Product Positions/Portfolio
                8.4.10.5 GlaxoSmithKline Key Developments
        8.4.11 Incyte Corporation
                8.4.11.1 Business Description
                8.4.11.2 Incyte Corporation Geographic Operations
                8.4.11.3 Incyte Corporation Financial Information
                8.4.11.4 Incyte Corporation Product Positions/Portfolio
                8.4.11.5 Incyte Corporation Key Developments
        8.4.12 Jazz Pharmaceuticals
                8.4.12.1 Business Description
                8.4.12.2 Jazz Pharmaceuticals Geographic Operations
                8.4.12.3 Jazz Pharmaceuticals Financial Information
                8.4.12.4 Jazz Pharmaceuticals Product Positions/Portfolio
                8.4.12.5 Jazz Pharmaceuticals Key Developments
        8.4.13 Kadmon Corporation
                8.4.13.1 Business Description
                8.4.13.2 Kadmon Corporation Geographic Operations
                8.4.13.3 Kadmon Corporation Financial Information
                8.4.13.4 Kadmon Corporation Product Positions/Portfolio
                8.4.13.5 Kadmon Corporation Key Developments
        8.4.14 MaaT Pharma
                8.4.14.1 Business Description
                8.4.14.2 MaaT Pharma Geographic Operations
                8.4.14.3 MaaT Pharma Financial Information
                8.4.14.4 MaaT Pharma Product Positions/Portfolio
                8.4.14.5 MaaT Pharma Key Developments
        8.4.15 Medac
                8.4.15.1 Business Description
                8.4.15.2 Medac Geographic Operations
                8.4.15.3 Medac Financial Information
                8.4.15.4 Medac Product Positions/Portfolio
                8.4.15.5 Medac Key Developments
        8.4.16 Millennium Pharmaceuticals/Takeda Oncology
                8.4.16.1 Business Description
                8.4.16.2 Millennium Pharmaceuticals/Takeda Oncology Geographic Operations
                8.4.16.3 Millennium Pharmaceuticals/Takeda Oncology Financial Information
                8.4.16.4 Millennium Pharmaceuticals/Takeda Oncology Product Positions/Portfolio
                8.4.16.5 Millennium Pharmaceuticals/Takeda Oncology Key Developments
        8.4.17 Novartis
                8.4.17.1 Business Description
                8.4.17.2 Novartis Geographic Operations
                8.4.17.3 Novartis Financial Information
                8.4.17.4 Novartis Product Positions/Portfolio
                8.4.17.5 Novartis Key Developments
        8.4.18 OncoImmune/Merck (MSD)
                8.4.18.1 Business Description
                8.4.18.2 OncoImmune/Merck (MSD) Geographic Operations
                8.4.18.3 OncoImmune/Merck (MSD) Financial Information
                8.4.18.4 OncoImmune/Merck (MSD) Product Positions/Portfolio
                8.4.18.5 OncoImmune/Merck (MSD) Key Developments
        8.4.19 Pfizer
                8.4.19.1 Business Description
                8.4.19.2 Pfizer Geographic Operations
                8.4.19.3 Pfizer Financial Information
                8.4.19.4 Pfizer Product Positions/Portfolio
                8.4.19.5 Pfizer Key Developments
        8.4.20 Regimmune Corporation
                8.4.20.1 Business Description
                8.4.20.2 Regimmune Corporation Geographic Operations
                8.4.20.3 Regimmune Corporation Financial Information
                8.4.20.4 Regimmune Corporation Product Positions/Portfolio
                8.4.20.5 Regimmune Corporation Key Developments
        8.4.21 Roche-Genentech
                8.4.21.1 Business Description
                8.4.21.2 Roche-Genentech Geographic Operations
                8.4.21.3 Roche-Genentech Financial Information
                8.4.21.4 Roche-Genentech Product Positions/Portfolio
                8.4.21.5 Roche-Genentech Key Developments
        8.4.22 Syndax Pharmaceutical
                8.4.22.1 Business Description
                8.4.22.2 Syndax Pharmaceutical Geographic Operations
                8.4.22.3 Syndax Pharmaceutical Financial Information
                8.4.22.4 Syndax Pharmaceutical Product Positions/Portfolio
                8.4.22.5 Syndax Pharmaceutical Key Developments
        8.4.23 Synthetic Biologics
                8.4.23.1 Business Description
                8.4.23.2 Synthetic Biologics Geographic Operations
                8.4.23.3 Synthetic Biologics Financial Information
                8.4.23.4 Synthetic Biologics Product Positions/Portfolio
                8.4.23.5 Synthetic Biologics Key Developments
        8.4.24 Takeda
                8.4.24.1 Business Description
                8.4.24.2 Takeda Geographic Operations
                8.4.24.3 Takeda Financial Information
                8.4.24.4 Takeda Product Positions/Portfolio
                8.4.24.5 Takeda Key Developments
        8.4.25 Xenikos
                8.4.25.1 Business Description
                8.4.25.2 Xenikos Geographic Operations
                8.4.25.3 Xenikos Financial Information
                8.4.25.4 Xenikos Product Positions/Portfolio
                8.4.25.5 Xenikos Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Graft Versus Host Disease (GVHD) Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Graft Versus Host Disease (GVHD) Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Graft Versus Host Disease (GVHD) Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Graft Versus Host Disease (GVHD) Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Graft Versus Host Disease (GVHD) Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Graft Versus Host Disease (GVHD) Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Graft Versus Host Disease (GVHD) Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Graft Versus Host Disease (GVHD) Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Graft Versus Host Disease (GVHD) Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Graft Versus Host Disease (GVHD) Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Graft Versus Host Disease (GVHD) Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Graft Versus Host Disease (GVHD) Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Graft Versus Host Disease (GVHD) Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Graft Versus Host Disease (GVHD) Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Graft Versus Host Disease (GVHD) Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Graft Versus Host Disease (GVHD) Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Graft Versus Host Disease (GVHD): Market Segmentation 
FIG. 2 Global Graft Versus Host Disease (GVHD) Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Graft Versus Host Disease (GVHD) Market, By Type I, 2019 (US$ Mn) 
FIG. 5 Global Graft Versus Host Disease (GVHD) Market, By Application I, 2019 (US$ Mn) 
FIG. 6 Global Graft Versus Host Disease (GVHD) Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Graft Versus Host Disease (GVHD) Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Graft Versus Host Disease (GVHD) Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Graft Versus Host Disease (GVHD) Providers, 2019
FIG. 11 Global Graft Versus Host Disease (GVHD) Market Revenue Contribution, By Type I, 2019 & 2028 (Value %) 
FIG. 12 Global Graft Versus Host Disease (GVHD) Market Revenue Contribution, By Application I, 2019 & 2028 (Value %) 
FIG. 13 Global Graft Versus Host Disease (GVHD) Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Graft Versus Host Disease (GVHD) Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Graft Versus Host Disease (GVHD) Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Graft Versus Host Disease (GVHD) Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Graft Versus Host Disease (GVHD) Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Graft Versus Host Disease (GVHD) Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Graft Versus Host Disease (GVHD) market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Graft Versus Host Disease (GVHD) Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Graft Versus Host Disease (GVHD) Market Value, By Segment1, 2018 – 2028
TABLE  North America Graft Versus Host Disease (GVHD) Market Value, By Segment2, 2018 – 2028
TABLE  North America Graft Versus Host Disease (GVHD) Market Value, By Country, 2018 – 2028
TABLE  Europe Graft Versus Host Disease (GVHD) Market Value, By Segment1, 2018 – 2028
TABLE  Europe Graft Versus Host Disease (GVHD) Market Value, By Segment2, 2018 – 2028
TABLE  Europe Graft Versus Host Disease (GVHD) Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Graft Versus Host Disease (GVHD) Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Graft Versus Host Disease (GVHD) Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Graft Versus Host Disease (GVHD) Market Value, By Country, 2018 – 2028
TABLE  Latin America Graft Versus Host Disease (GVHD) Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Graft Versus Host Disease (GVHD) Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Graft Versus Host Disease (GVHD) Market Value, By Country, 2018 – 2028
TABLE  MEA Graft Versus Host Disease (GVHD) Market Value, By Segment1, 2018 – 2028
TABLE  MEA Graft Versus Host Disease (GVHD) Market Value, By Segment2, 2018 – 2028
TABLE  MEA Graft Versus Host Disease (GVHD) Market Value, By Country, 2018 – 2028
TABLE  AltruBio: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Amgen: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Biogen: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bristol-Myers Squibb: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  CSL Behring: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  CTI BioPharma: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ElsaLys Biotech (Mediolanum Farmaceutici Spa): Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Equillium/Biocon: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Incyte Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Jazz Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Kadmon Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  MaaT Pharma: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Medac: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Millennium Pharmaceuticals/Takeda Oncology: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  OncoImmune/Merck (MSD): Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Regimmune Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Roche-Genentech: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Syndax Pharmaceutical: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Synthetic Biologics: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Takeda: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Xenikos: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Graft Versus Host Disease (GVHD) Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Graft Versus Host Disease (GVHD) Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Graft Versus Host Disease (GVHD) Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Graft Versus Host Disease (GVHD) Market, By Geography, 2019 (US$ Mn)
FIG.  Global Graft Versus Host Disease (GVHD) Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Graft Versus Host Disease (GVHD) Providers, 2016
FIG.  Global Graft Versus Host Disease (GVHD) Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Type I Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Type II Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Type III Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Graft Versus Host Disease (GVHD) Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Application I Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Application II Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Application III Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Graft Versus Host Disease (GVHD) Market Value, 2018 – 2028, (US$ Mn)